ATE491948T1 - Gpr30-östrogenrezeptor bei mammakarzinomen - Google Patents

Gpr30-östrogenrezeptor bei mammakarzinomen

Info

Publication number
ATE491948T1
ATE491948T1 AT07763452T AT07763452T ATE491948T1 AT E491948 T1 ATE491948 T1 AT E491948T1 AT 07763452 T AT07763452 T AT 07763452T AT 07763452 T AT07763452 T AT 07763452T AT E491948 T1 ATE491948 T1 AT E491948T1
Authority
AT
Austria
Prior art keywords
gpr30
estrogen receptor
mammary cancer
antibodies
ligands
Prior art date
Application number
AT07763452T
Other languages
English (en)
Inventor
Edward Filardo
Edmond Sabo
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ATE491948T1 publication Critical patent/ATE491948T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07763452T 2006-02-06 2007-02-06 Gpr30-östrogenrezeptor bei mammakarzinomen ATE491948T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77104906P 2006-02-06 2006-02-06
US85610106P 2006-11-01 2006-11-01
PCT/US2007/003128 WO2007092431A2 (en) 2006-02-06 2007-02-06 Gpr30 estrogen receptor in breast cancers

Publications (1)

Publication Number Publication Date
ATE491948T1 true ATE491948T1 (de) 2011-01-15

Family

ID=38345735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07763452T ATE491948T1 (de) 2006-02-06 2007-02-06 Gpr30-östrogenrezeptor bei mammakarzinomen

Country Status (6)

Country Link
US (1) US7803561B2 (de)
EP (1) EP1982181B1 (de)
AT (1) ATE491948T1 (de)
CA (1) CA2642419A1 (de)
DE (1) DE602007011206D1 (de)
WO (1) WO2007092431A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1620128A1 (de) * 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonisten kombiniert mit renin-angiotensin-aldosteron-system antagonisten zur behandlung renaler insuffizienz
WO2010006703A1 (en) * 2008-07-15 2010-01-21 Bayer Schering Pharma Aktiengesellschaft G-protein coupled receptor 30 (gpr30) knockout mice as a model for cardiovascular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
EP1690934A3 (de) * 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0586505A1 (de) 1991-05-14 1994-03-16 Repligen Corporation Heterokonjugat-antikörper zur behandlung von hiv-infektionen
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2005099363A2 (en) * 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
WO2006005468A1 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 30 (gpr30)

Also Published As

Publication number Publication date
US7803561B2 (en) 2010-09-28
US20080131915A1 (en) 2008-06-05
DE602007011206D1 (de) 2011-01-27
WO2007092431A2 (en) 2007-08-16
WO2007092431A3 (en) 2008-07-10
EP1982181A2 (de) 2008-10-22
CA2642419A1 (en) 2007-08-16
EP1982181B1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
IL258880A (en) Diarylhydantoin compounds
EP3461847A8 (de) Humanisierte antikörper gegen liv-1 und deren verwendung zur behandlung von krebs
CY1119290T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1116970T1 (el) Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης
EP2331136A4 (de) Frizzled-bindende stoffe und ihre verwendungen
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
IL196470A (en) Antagonist antibody for the treatment of cancer
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
EA201201000A1 (ru) Способы лечения колоректального рака
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
MX352373B (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
DK1766056T3 (da) Oligonukleotider til brystcancerdiagnose
EP2106442A4 (de) Antikörper zur modifikation krebsartiger krankheiten
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
EP2104732A4 (de) Antikörper zur modifikation krebsartiger krankheiten
ATE422162T1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
EP2106441A4 (de) Antikörper zur modifikation krebsartiger krankheiten
ATE491948T1 (de) Gpr30-östrogenrezeptor bei mammakarzinomen
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties